东曜药业股份有限公司（股票代码：01875，股票名称：东曜药业-B）于2026年8月5日公布截至2026年7月31日的证券变动月报表。报告显示，公司上月底及本月底的已发行普通股总数均为772,787,887股，库存股数量保持为零，整体股本结构与上月底相比无变化。
根据公告，东曜药业-B当月未发生任何新增股份发行、股份购回或注销等变动；公司已授出的首次公开发售前购股权计划（每股行使价为0.286美元，即每股2.2335港元）期末结余为20,000份，与上月底持平，本月无行权新增发行或失效情形。公司确认符合香港联交所《上市规则》要求，公众持股量满足相关监管规定。
本次月报由公司联席公司秘书吕颖一签署。公司表示，将继续严格遵守相关上市规则、法律及其他监管要求，确保公司治理与信息披露的规范性。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.